Tuesday, October 4, 2022


Biotechnology News Magazine

Prosetta Biosciences Announces Novel Solution to COVID-19 Crisis

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

January 19, 2021

Prosetta Biosciences, located in San Francisco, California, is a biotechnology company that has developed novel small-molecule drugs that research indicates are effective not only against the COVID-19 virus, but against other virus families that cause respiratory disease, including influenza and the common cold – without the liability of drug resistance development.

The compounds work in a new way: instead of interfering with the virus’s own functions, as do traditional antiviral drugs, this approach targets a newly appreciated structure within human cells that is hijacked and altered by viruses when they infect the cell, as part of their replication process.

A large body of work suggests that to be successful a virus must not only reconfigure and redirect host cell machinery needed for its replication, but must also block the fundamental host defense termed innate immunity. Novel biochemical readouts of both of these viral actions have been established by the Prosetta team, and the new drugs shown to oppose the virus on both fronts.

Prosetta Biosciences notes the new drugs are also shown to avoid development of resistance due to viral mutations, an important liability of vaccines and conventional anti-viral drugs.

As noted, these new drugs are effective not only against coronaviruses, but also against the other major human respiratory viruses (influenza, RSV, adenovirus, rhinovirus and herpesviruses). This has obvious implications for the successful deployment of the compounds against the current and future pandemic threats, whether from new mutations of SARS-CoV-2 or other new strains of respiratory viruses including influenza. Prosetta’s manuscript can be accessed at:


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine